Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 55 pages | ID: TE315D1C835DEN
Global Markets Direct

Abstracts

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 2, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Respiratory, Dermatology, Musculoskeletal Disorders, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Metabolic Disorders and Oncology which include indications Idiopathic Pulmonary Fibrosis, Fibrosis, Neuropathic Pain (Neuralgia), Cardiomyopathy, Coronavirus Disease 2019 (COVID-19), Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Skin Inflammation and Wounds.

The latest report Type 2 Angiotensin II Receptor - Drugs In Development, 2022, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
• The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction
Global Markets Direct Report Coverage
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
Confo Therapeutics SA
HK inno.N Corp
MorphoSys AG
Novopyxis Inc
Shandong Danhong Pharmaceutical Co Ltd
Vicore Pharma AB
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
(amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
Product Description
Mechanism Of Action
History of Events
C-106 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CFTX-1554 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NP-6A - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
thalidomide - Drug Profile
Product Description
Mechanism Of Action
History of Events
VP-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VP-03 - Drug Profile
Product Description
Mechanism Of Action
History of Events
WXSH-0024 - Drug Profile
Product Description
Mechanism Of Action
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
Featured News & Press Releases
Jun 28, 2022: Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody drug discovery and development technology in rare diseases
Jun 17, 2022: Vicore Pharma starts Phase I trial of angiotensin II type 2 receptor agonist
Jun 03, 2022: Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients
Mar 18, 2022: Vicore initiates human forearm blood flow study with C21
Mar 10, 2022: Confo Therapeutics doses first subjects in phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain
Mar 10, 2022: Confo Therapeutics doses first subjects in phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain
Mar 09, 2022: Vicore strengthens rare lung disease pipeline with PAH indication
Mar 04, 2022: Vicore to host R&D-Day
Mar 04, 2022: Vicore to host R&D Day
Feb 10, 2022: Vicore's AIR study interim analysis suggests that C21 improves lung function in IPF patients
Dec 15, 2021: Confo Therapeutics expands patent estate for ConfoBody-based GPCR screening platform
Nov 02, 2021: Vicore's C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study
Oct 25, 2021: Vicore Pharma Holding: Lancet’s EClinicalMedicine publishes phase 2 data on C21 in COVID-19
Sep 22, 2021: Vicore to host Key Opinion Leader webinar on C21 for the treatment of idiopathic pulmonary fibrosis (IPF)
Sep 22, 2021: Vicore obtains SARS coronavirus patent for C21 in the USA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Confo Therapeutics SA, 2022
Pipeline by HK inno.N Corp, 2022
Pipeline by MorphoSys AG, 2022
Pipeline by Novopyxis Inc, 2022
Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022
Pipeline by Vicore Pharma AB, 2022
Dormant Projects, 2022
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022